OrbiMed Advisors KNSA Position
Active4-Fund ConvergenceOrbiMed Advisors initiated a new position in Kiniksa Pharmaceuticals International, plc (KNSA) in Q4 2025, holding $7.7M worth of shares across 187,199 shares.
KNSA is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for KPL-387 in 624 days (Dec 31, 2027), making the timing of OrbiMed's position particularly relevant.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Full company profile →Short Interest
8.9%
5.3 days to cover
Frequently Asked Questions
Does OrbiMed Advisors own KNSA?
Yes. As of Q4 2025, OrbiMed Advisors holds 187,199 shares of Kiniksa Pharmaceuticals International, plc (KNSA) valued at $7.7M. This data comes from their SEC 13F filing.
How many hedge funds own KNSA?
4 specialist biotech hedge funds currently hold KNSA, including Baker Bros. Advisors, Tang Capital Management, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy KNSA?
OrbiMed Advisors's position in KNSA was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's KNSA position increasing or decreasing?
OrbiMed Advisors initiated a new position in KNSA in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KNSACompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →